Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.
Checking for remaining leukemia cells after treatment predicts who will do better, making this test useful for monitoring real patients.
MRD negativity after frontline azacitidine+venetoclax was strongly prognostic for superior overall and event-free survival in AML in this large multicenter French VENAURA registry. Real-world data establishes MRD monitoring as a clinically meaningful endpoint in this now-standard regimen.
What the study was
- Study design
- multicenter_registry_cohort
- Category
- hematologic_malignancies
- Maturity
- Potentially Practice-Changing
Why it surfaced
High-impact real-world registry study in AML with aza+ven—the current frontline standard. MRD endpoint is critical for future trial design and treatment escalation decisions. Published in Leukemia; multicenter design and large cohort give high confidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.